目的 探讨复方苦参注射液联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床疗效。方法 选取2018年3月—2022年3月天津市宝坻区人民医院胸外科收治的68例非小细胞肺癌伴恶性胸腔积液患者，按随机数字表法分为治疗组和对照组，每组各34例。对照组给予注射用顺铂40 mg/次、地塞米松10 mg/次，用生理盐水50 mL稀释后，通过胸腔闭式引流管进行胸腔缓慢注入。治疗组在对照组的治疗基础上给予复方苦参注射液30 mL，所有药物与生理盐水共加至50 mL，腔内缓慢注入。注入药物后胸腔闭式引流管夹闭24 h，1次/周，连用3次为一疗程。两组治疗1个疗程。观察两组患者的临床疗效，比较生活质量改善情况，胸腔积液中癌胚抗原（CEA）、血管内皮生长因子（VEGF）水平和不良反应发生情况。结果 治疗后，治疗组总有效率为79.41%，显著高于对照组的55.88%（P＜0.05）。治疗后，两组患者VEGF、CEA水平较治疗前均显著降低（P＜0.05）；且治疗组较对照组降低更为明显（P＜0.05）。生活质量方面，治疗组总有效率是91.18%，显著优于对照组的70.59%（P＜0.05）。治疗后，治疗组胃肠道反应和骨髓抑制发生率明显低于对照组（P＜0.05）。结论 复方苦参注射液联合顺铂治疗非小细胞肺癌恶性胸腔积液具有较好的临床疗效，可提升患者的生活质量，减少药物的不良反应。

Objective To observe the clinical efficacy of Compound Kushen Injection combined with cisplatin in treatment of non-small cell lung cancer malignant pleural effusion. Methods A total of 68 patients with non-small cell lung cancer with malignant pleural effusion admitted to the Thoracic Surgery Department of Tianjin Baodi District People's Hospital from March 2018 to March 2022 were selected and divided into treatment group and control group according to random number table method, with 34 cases in each group. Patients in the control group were iv administered with Cisplatin for injection, 40 mg/time, dexamethasone 10 mg/time, diluted with 50 mL normal saline, and slowly injected into the chest through a closed thoracic drainage tube. Patients in the treatment group were iv administered with 30mL of Compound Kushen Injection on the basis of the control group, all drugs were added to 50 mL normal saline and injected into the cavity slowly. After drug injection, the closed thoracic drainage tube was clamped for 24 h, once a week, for 3 consecutive times as a course. Two groups were treated for 1 course. The clinical efficacy of the two groups of patients was observed, and the improvement of quality of life, the levels of carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) in pleural effusion and the occurrence of adverse reactions were compared. Results After treatment, the total effective rate of the treatment group was 79.41%, which was significantly higher than that of the control group (55.88%) (P < 0.05). After treatment, VEGF and CEA levels in two groups were significantly decreased compared with those before treatment (P < 0.05). The decrease was more obvious in the treatment group than that in the control group (P < 0.05). In terms of quality of life, the total effective rate of the treatment group was 91.18%, which was significantly better than that of the control group (70.59%) (P < 0.05). After treatment, the incidence of gastrointestinal reaction and myelosuppression in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Compound Kushen Injection combined with cisplatin has good clinical effect in treatment of advanced non-small cell lung cancer malignant pleural effusion, and can improve the life quality of patients, reduce adverse reactions, which has important application value in clinical treatment.

R979.1